S | M | T | W | T | F | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 | 31 |
News & Announcements
- 2019 aAPI Annual Meeting
Sep 21, 2019
Alabama API Annual Meeting 2019Saturday morning CME ProgramSeptember 21, 7:30am to 1:00pmAC Marriott435 Williams Avenue SW, Huntsville, ALMessage: -C ... - aAPI SCHOLARSHIP FUND: Deadline for application submission this year is July 31, 2019
Jul 31, 2019
https://www.alabamaapi.org/aAPI-Scholarship ... - View pictures from aAPI 2013 Annual meeting
Jan 1, 2014
Friday November 15, 2013:http://alabamaapi.org/aAPI-2013-annual-meetingFriday Saturday November 16, 2013: CME & Cruise:http://alabamaapi. ...
News
« Back to Recent NewsTradjenta (linagliptin) tablets and Jentadueto (linagliptin/metformin HCI) tablets: Focusing on What Matters, Improving Glycemic Control for Adult Patients With Type 2 Diabetes
Aug 27, 2013
Date & Time: August 27th, 2013 Tuesday, 6:30pm
Location: Sitar Indian Cuisine
Address: 420 Jordan Ln NW Huntsville, AL 35805 (256) 536-3360
Hosted By: Gary Otten, Boehringer-Ingelheim.and Shashi Kumr MD, aAPI
Message: Please register for this program today.
3 WAYS TO REGISTER:
1. RSVP thru the pingg e-mail you received.
2. Contact Shashi Kumar at shashikumaram@yahoo.com
3. Click the link below to register on our aAPI website.
http://www.alabamaapi.org/calendar_detail.asp?id=5971
Under the Physician Payment Sunshine Act Final Rule (Open Payments), beginning August 1, 2013 Pharma will be required to report all payments and transfers of value to physicians to the Centers for Medicare and Medicaid services (CMS).
This program is open to healthcare practitioners (HCPs) for whom the information presented is relevant to their practice. Spouses or guests cannot be accommodated. By registering for this event I agree to allow Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), Lilly USA, LLC, and third parties associated with the execution of this program to contact me, by phone, fax, e-mail, or in person. BIPI and Lilly USA, LLC have adopted the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals that went into effect on July 1, 2002. Pursuant to the Code, inclusion of healthcare professionals’ spouses or guests is not permitted. We appreciate your understanding and support of our commitment to following TRADJENTA® (LINAGLIPTIN) TABLETS
INDICATION AND IMPORTANT LIMITATIONS OF USE
TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
TRADJENTA is contraindicated in patients with a history of hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity.
WARNINGS AND PRECAUTIONS
Pancreatitis
There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue TRADJENTA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA.
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with TRADJENTA or any other antidiabetic drug.
Member Highlight

Amit Chakrabarty, MD, MS, FRCS, FICS
Click here to learn more...
Resources
AAPI
CDC
AMA
Alabama Medical Board
Medical Association of AL

